Overview
Management of Decompensated HCV Cirrhotic Patients
Status:
Completed
Completed
Trial end date:
2018-06-24
2018-06-24
Target enrollment:
0
0
Participant gender:
All
All
Summary
-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV) remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with complications as worsening decompensation. The impact of DAAs therapy on mortality in decompensated cirrhosis was not investigated.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Zagazig UniversityTreatments:
Antiviral Agents
Furosemide
Ribavirin
Silymarin
Sofosbuvir
Spironolactone
Vitamin K
Vitamin K 1
Criteria
Inclusion Criteria:- chronic active HCV proved by the positivity of HCV RNA, elevated transaminases.
- CTP score was >9, MELD score was <29
- Decompensated cirrhosis with frequent hepatic encephalopathy (HE) or difficult to
treat ascites
Exclusion Criteria:
- exposure to previous antiviral therapy
- hepatocellular carcinoma
- other causes of liver diseases or mixed causes (excessive alcohol consumption,
autoimmune liver disease)
- previous liver transplantation.